Beta Bionics, Inc. (BBNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...
Add Yahoo as a preferred source to see more of our stories on Google. Beta Bionics said it plans to integrate its ILet Bionic Pancreas automated insulin delivery system with a glucose-ketone sensor ...
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of Bionic Insights™ , an innovative new feature within its Bionic Reports, designed to help healthcare ...
IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its ...
Beta Bionics (BBNX) reported preliminary, unaudited Q4 2025 net sales of at least $32M, compared to estimate of $28.9M, representing growth of at least 56% Y/Y. DME channel net sales are expected to ...
Beta Bionics (NASDAQ:BBNX) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, ...
Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Gross margin of 55.5%, up 212 basis points compared to 53.4% in the third quarter of 2024. Installed customer ...
Damiano, a professor at Boston University and the chief executive of a promising start-up called Beta Bionics, was there to support a new generation of continuous glucose monitoring technology – part ...
Irvine-based Beta Bionics, which recently went public, saw two-year revenue increase more than eight-fold to $103.2 million.
Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results